Chronic rhinitis in South Africa – more than just allergy!

Chronic rhinitis is a troublesome condition for sufferers. It is tempting to label all patients with chronic nasal symptoms as having allergic rhinitis (AR), but many such patients have other causes of chronic rhinitis that need a specific diagnosis and management strategy. Even when the patient fully fits the definition of AR, their condition will be best served by combining medication with ongoing patient education.http://www.samj.org.zaam2021OtorhinolaryngologyPaediatrics and Child Healt

Vocabulaire contrôlé multilingue et multi-classification Partie 1

Serveur Terminologique – Recherche préliminaire en rapport avec le développement d’un serveur belge de terminologie dans le secteur de la santé, projet financé par le SPF Santé Publique, MIM asbl ed., Bruxelles, 31 octobre 201

Challenging beliefs : only a genetic diagnosis of primary immunodeficiency disorders will suffice for some patients, even in a resource-poor setting

Genetic testing has become important in the repertoire for the diagnosis of primary immunodeficiencies. More than 350 genetic disorders have been molecularly characterised since the first description of primary immunodeficiencies. Some authorities regard the first description of Bruton agammaglobulinaemia in 1952 as the foundation of this field, whereas others refer to the first description of neutropaenia in 1922 as its origin. Genetic testing for primary immunodeficiencies is important in order to make a definitive diagnosis, to guide definitive treatment, to arrive at a prognosis, to make prenatal genetic diagnoses, for family planning and to evaluate the risk to other family members. Primary immunodeficiencies often present in various ways, with overlapping symptoms. In resource-poor countries, primary immunodeficiency diagnoses and classifications are often based on the availability of a few basic tests with which only a probable diagnosis can be provided. To a large extent, this influences both management and outcome. In this case series, we describe eight patients in whom next-generation sequencing has proved to be of value in making a definitive diagnosis. Such diagnosis has helped practitioners to guide directed therapy, counsel family members appropriately, enable prenatal testing, predict prognosis and explain the symptoms of family members, including carrier mothers. The series also emphasises the value of and the necessity for genetic testing in resource-limited settings.http://www.journals.co.za/content/journal/caciam2020Paediatrics and Child Healt

Chronic rhinitis in South Africa – more than just allergy!

Chronic rhinitis is a troublesome condition for sufferers. It is tempting to label all patients with chronic nasal symptoms as having allergic rhinitis (AR), but many such patients have other causes of chronic rhinitis that need a specific diagnosis and management strategy. Even when the patient fully fits the definition of AR, their condition will be best served by combining medication with ongoing patient education

Argumentaire structuré Partie 2

Serveur Terminologique – Recherche préliminaire en rapport avec le développement d’un serveur belge de terminologie dans le secteur de la santé,projet financé par le SPF Santé Publique, MIM asbl ed., Bruxelles, 31 octobre 201

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.

INTRODUCTION: Abiraterone acetate + prednisone (AAP) and docetaxel have proven their efficacy in the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) in clinical trials. However, real-world data are scarce. The goal of this study is to evaluate real-world data on the efficacy and safety of these therapies in mHSPC patients. PATIENTS AND METHODS: Records of 93 patients from 21 different centres were retrospectively reviewed. Primary and secondary endpoints were radiographic and PSA progression-free survival (RPFS - PSA-PFS) and cancer specific and overall survival (CSS - OS), respectively. Adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Differences in oncological outcome and AEs were evaluated between three treatment groups: ADT only (N=26) - ADT + AAP (N=48) - ADT + docetaxel (N=19). Survival analysis was performed using Kaplan-Meier statistics. RESULTS: Median RPFS was 13 months (95% confidence interval [CI]: 9-17) for ADT only, 21 months (95% CI: 19-23) for ADT + AAP and 12 months (95% CI: 11-14) for ADT + docetaxel (p = 0.004). The 1-year PSA-PFS, CSS and OS were 73.5%, 90.7% and 88.7%, respectively, with no significant differences between the three groups. Adverse events of grade 3 or higher were not observed more frequently. CONCLUSION: Retrospective real-world data show a significantly longer RPFS for mHSPC patients treated with ADT + AAP compared to ADT only or ADT + docetaxel at short-term follow-up. This can aid in counselling of mHSPC patients in daily clinical practice